Liquid-biopsy-Analysen mithilfe zellfreier DNA (cfDNA)

详细信息    查看全文

• 作者：Univ.-Prof. Dr. E. Dahl ; Dr. V. Kloten
• 关键词：Personalisierte Medizin ; Zielgerichtete Therapien ; Treibermutationen ; EGFR ; Mutationen ; Response ; Monitoring ; Precision medicine ; Targeted therapy ; Driver mutations ; EGFR mutations ; Response monitoring
• 刊名：Der Pathologe
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：36
• 期：6
• 页码：572-578
• 全文大小：629 KB
• 参考文献：1.Agassi R, Czeiger D, Shaked G et al (2015) Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. Am J Clin Pathol 143:18-4CrossRef PubMed
  2.Alix-Panabieres C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59:110-18CrossRef PubMed
  3.Alix-Panabieres C, Pantel K (2014) Challenges in circulating tumour cell research. Nat Rev Cancer 14:623-31CrossRef PubMed
  4.Ascierto PA, Minor D, Ribas A et al (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31:3205-211
  5.Bastian PJ, Palapattu GS, Yegnasubramanian S et al (2007) Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res 13:5361-367CrossRef PubMed
  6.Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24PubMedCentral CrossRef PubMed
  7.Church TR, Wandell M, Lofton-Day C et al (2014) Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63:317-25PubMedCentral PubMed
  8.Conor E, Steuer MD, Fadlo R et al (2014) The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer 121:E1–E6
  9.Couraud S, Labonne S, Missy P et al (2013) Lung cancer in never smokers: a French national cohort (BioCAST/IFCT-1002). Rev Mal Respir 30:576-83CrossRef PubMed
  10.Couraud S, Souquet PJ, Paris C et al (2015) BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. Eur Respir J 45:1403-414CrossRef PubMed
  11.Dawson SJ, Rosenfeld N, Caldas C (2013) Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 369:93-4CrossRef PubMed
  12.Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579-86CrossRef PubMed
  13.Fackler MJ, Lopez BZ, Umbricht C et al (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-170PubMedCentral CrossRef PubMed
  14. Forshew T, Murtaza M, Parkinson C et al (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4:136ra68CrossRef PubMed
  15.Grutzmann R, Molnar B, Pilarsky C et al (2008) Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 3:e3759PubMedCentral CrossRef PubMed
  16.Herman JG (2004) Circulating methylated DNA. Ann N Y Acad Sci 1022:33-9CrossRef PubMed
  17.Hindson BJ, Ness KD, Masquelier DA et al (2011) High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83:8604-610PubMedCentral CrossRef PubMed
  18. http://?www.?wsj.?com/?articles/?eric-topol-and-stephen-r-quake-a-stethoscope-for-the-next-200-years-1420242913
  19.Hua Z, Rouse JL, Eckhardt AE et al (2010) Multiplexed real-time polymerase chain reaction on a digital microfluidic platform. Anal Chem 82:2310-316PubMedCentral CrossRef PubMed
  20.Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659-665PubMed
  21.Kloten V, Birte B, Winner K et al (2013) Promoter hypermethylation of the tumorsuppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res 15:R4PubMedCentral CrossRef PubMed
  22. Leon SA, Shapiro B, Sklaroff DM et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646-50PubMed
  23.Li M, Chen WD, Papadopoulos N et al (2009) Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 27:858-63PubMedCentral CrossRef PubMed
  24. Lofton-Day C, Model F, deVos T et al (2008) DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54:414-23CrossRef PubMed
  25.Mandel P, Metais P (1948) Les acides nucléiques du plasma san-guin chez l’Homme. C R Seances Soc Biol Fil 142:241-43PubMed
  26.Metzker ML (2010) Sequencing technologies -the next generation. Nat Rev Genet 11:31-6CrossRef PubMed
  27.Misale S, Yaeger R, Hobor S et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-36PubMedCentral PubMed
  28.Mok TS, Wu YL, Soo LJ et al (2015) Detection and Dynamic Changes of EGFR Mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21(14):3196-203CrossRef PubMed
  29.Murtaza M, Dawson SJ, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to c
• 作者单位：Univ.-Prof. Dr. E. Dahl (1) (2) (3)
  Dr. V. Kloten (1)
  
  1. Arbeitsgruppe Molekulare Onkologie, Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland
  2. Molekularpathologische Diagnostik, Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland
  3. RWTH zentralisierte Biomaterialbank (RWTH cBMB), Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pathology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1963

文摘

Molecular biological analysis of nucleic acids in blood or other bodily fluids (i.e. liquid biopsy analyses) may supplement the pathologists-diagnostic armamentarium in a reasonable way—particularly in cancer precision medicine. Within the field of oncology, liquid biopsy can potentially be used to monitor tumor burden in the blood and to early detect emerging resistance in the course of targeted cancer therapies. An already approved application of liquid biopsy is the detection of epidermal growth factor receptor (EGFR) driver mutations in blood samples of lung cancer patients in those cases where no tissue biopsy is available. However, there is still currently considerable insecurity associated with blood-based DNA analytic methods that must be solved before liquid biopsy can be implemented for broader routine application in the diagnosis of cancer. In this article, the current state of development of liquid biopsy in molecular diagnostics from a pathology point of view is presented. Keywords Precision medicine Targeted therapy Driver mutations EGFR mutations Response monitoring